

COMPLETE IF KNOWN

Application Number	10/585,147
Filing Date	June 29, 2006
First Named Inventor	Christopher Bayly
Group Art Unit	To be assigned
Examiner Name	To be assigned
Attorney Docket Number	MC099YP

(use as many sheets as necessary)

1 of 3

Attorney Docket Number	MC099YP
------------------------	---------

[illegible]

Examiner Initials*	Cite No.	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number Kind Code (if known)		
			WO 2004/033445	Merck Frosst Canada & Co.	04/22/2004
			WO 98/50533	Smithkline Beecham Corporation	11/12/1998
			WO 98/05336	Smithkline Beecham Corporation	02/12/1998
			WO 01/70232	Smithkline Beecham Corporation	09/27/2001
			WO 01/95911	Smithkline Beecham Corporation	12/20/2001
			WO 00/69855	Medivir UK Limited	11/23/2000
			WO 02/088106	Medivir AB	11/07/2002
			WO 02/057248	Incenta Limited	07/25/2002
			WO 02/057270	Incenta Limited	07/25/2002
			WO 02/057246	Incenta Limited	07/25/2002

03/25/2010

SEND TO Commissioner for Patents, P.O. Box 240, Alexandria, VA 22304-0240. Computer-generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 8/24/2006

STATEMENT BY APPLICANT

COMPLETE IF KNOWN

Application Number	10/585,147
Filing Date	June 29, 2006
First Named Inventor	Christopher Bayly
Group Art Unit	To be assigned
Examiner Name	To be assigned
Attorney Docket Number	MC099YP

Sheet

2

of

3

Attorney Docket Number	MC099YP
------------------------	---------

Examiner
Initials*Cite
No.

U.S. Patent Document

Number

Kind Code (if known)

Name of Patentee or Applicant
of Cited Document

Date of Publication of
Cited Document
MM-DD-YYYY

Examiner
Initials*Cite
No.

Foreign Patent Document

Office

Number

Kind
Code
(if known)Name of Patentee or Applicant
of Cited Document

Date of Publication of
Cited Document
MM-DD-YYYY

WO 02/057249

Incenta Limited

07/25/2002

Examiner
Signature

/ Bernard Dentz /

Date
Considered

03/25/2010

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 8/24/2006

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /B.D./

(use as many sheets as necessary)

Sheet

3

of

3

Attorney Docket Number

MC099YP

COMPLETE IF KNOWN

Application Number

10/585,147

Filing Date

June 29, 2006

First Named Inventor

Christopher Bayly

Group Art Unit

To be assigned

Examiner Name

To be assigned

NON PATENT LITERATURE DOCUMENTS

Examiner
Initials*Cite
No.

Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.

Saftig, P et al., PNAS: Proceedings of the National Academy of Sciences, Vol. 95, pp 13453-13458 (1998), "Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice"

Thompson, SK et al., PNAS: Proceedings of the National Academy of Sciences, Vol. 94, pp 14249-14254 (1997), "Design of potent and selective human cathepsin K inhibitors that span the active site"

Examiner
Signature

/Bernard Dentz/

Date
Considered

03/25/2010

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 8/24/2006

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /B.D./